Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating activities:    
Net loss $ (9,068) $ (7,652)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 659 438
Amortization expense - right-of-use assets - operating and finance leases 649 692
Stock-based compensation 2,687 2,169
Equity securities earned from research and development activities (132) 0
Other non-cash items (84) 0
Changes in operating assets and liabilities:    
Financial assets, net 1,103 (2,763)
Inventories (65) (330)
Prepaid expenses and other assets 70 (838)
Accounts payable 400 (246)
Accrued compensation and other accrued liabilities (1,731) 1,237
Other long-term liabilities (617) (624)
Deferred revenue (311) 6,492
Net cash used in operating activities (6,440) (1,425)
Investing activities:    
Purchase of property and equipment (2,550) (761)
Proceeds from sale of property and equipment 17 0
Net cash used in investing activities (2,533) (761)
Financing activities:    
Proceeds from exercises of stock options 1,223 39
Payments of lease obligations - Finance leases 0 (51)
Taxes paid related to net share settlement of equity awards (1,206) (1,007)
Net cash provided by (used in) financing activities 17 (1,019)
Net decrease in cash, cash equivalents and restricted cash (8,956) (3,205)
Cash, cash equivalents and restricted cash at the beginning of the period 150,817 92,221
Cash, cash equivalents and restricted cash at the end of the period 141,861 89,016
Supplemental disclosure of cash flow information:    
Interest paid 3 4
Capital expenditures incurred but not yet paid 579 182
Assets received for research and development revenue earned 900 0
Cash reconciliation:    
Total cash, cash equivalents and restricted cash $ 141,861 $ 89,016